Dinutuximab beta and Isotretinoin Therapy
P00548a
For the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.
Blinatumomab Paediatric Therapy
P00567a
As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell
Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy
P00707a
As monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of the consolidation therapy.
Pembrolizumab Paediatric Monotherapy
P00711a
As monotherapy for the treatment of paediatric patients aged 3 years and older with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option
P00711b
As monotherapy for the adjuvant treatment of adolescents aged 12 years
and older with Stage IIB or IIC melanoma and who have undergone
complete resection.